Research programme: anti-infectives - Zymenex

Drug Profile

Research programme: anti-infectives - Zymenex

Alternative Names: ACE 710; ACE 810; ACE 820; Anti-infectives research programme - Zymenex

Latest Information Update: 29 Nov 2016

Price : $50

At a glance

  • Originator ACE BioSciences
  • Developer Zymenex A/S
  • Class Antibodies; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Aspergillosis; Clostridium infections; Moraxella infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Aspergillosis in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for research development in Clostridium-infections in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for research development in Moraxella-infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top